Traditionally associated with allergy and anti-parasitic immunity, immunoglobulin E (IgE) has largely been overlooked as a therapeutic antibody class in oncology. However, a growing body of clinical evidence suggests that it may be capable of overcoming some of the limitations of existing antibody-based therapies. Given the cost, limited access and toxicity challenges of some immunotherapy options, the industry is seeking the next wave of innovation, where IgE is emerging as an unexpected candidate.
© Drug Discovery & Development magazine, Autumn edition